ArticleCurrent urology reports2008
Transurethral collagen denaturation for women with stress urinary incontinence.
Article in Current urology reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Transurethral radiofrequency collagen denaturation for the treatment of women with urinary incontinence.The Cochrane database of systematic reviews · 2015Pooled it
- Early Feasibility Study to Evaluate the Viveve System for Female Stress Urinary Incontinence: Interim 6-Month Report.Journal of women's health (2002) · 2020Trial
- A 12-month feasibility study to investigate the effectiveness of cryogen-cooled monopolar radiofrequency treatment for female stress urinary incontinence.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2020Article
- Management of urinary incontinence.P & T : a peer-reviewed journal for formulary management · 2012Article
- Radiofrequency for the treatment of stress urinary incontinence in women.Current urology reports · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transurethral collagen denaturation was approved by the US Food and Drug Administration in 2005 for the nonsurgical treatment of stress urinary incontinence in women. In this procedure, controlled, nonablative radiofrequency energy applied through a transurethral probe produces microscopic submucosal sites of collagen denaturation, resulting in reduced tissue compliance. Treatment is administered in about 30 minutes in an outpatient setting without incisions, general anesthesia, or use of cystoscopy or other visualization. The safety and efficacy of this treatment were demonstrated in a pilot trial in 41 women and then in a subsequent 12-month sham procedure-controlled trial in more than 170 women. Ongoing clinical trials include a 3-year, open-label durability study and an evaluation of this technique in women who have failed prior surgical intervention. To date, patients who received transurethral collagen denaturation have experienced improvements in quality of life and in Valsalva leak point pressure. This procedure presents a beneficial nonsurgical treatment option for women with stress urinary incontinence.
Indexed as
Identifiers
18702921What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.